Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

39P - Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): Updated results of a randomized, open-label, phase II trial

Date

27 Jun 2024

Session

Poster Display session

Presenters

Liyu Su

Citation

Annals of Oncology (2024) 35 (suppl_1): S1-S74. 10.1016/annonc/annonc1477

Authors

L. Su1, P. Lin1, F. Huang1, Z. Ye1, H. Li1, C. Zhuo1, S. Wei1, S. Yu2, J. Li1, S. Zheng3, Y. Hong4, L. Zheng1, S. Zhao1, R. Lin5

Author affiliations

  • 1 Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou/CN
  • 2 Fujian Sanming First Hospital, Sanming/CN
  • 3 Fuzhou Second Hospital, Fuzhou/CN
  • 4 Quanzhou First Hospital, Quanzhou/CN
  • 5 Fujian Provincial Hospital, Fuzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 39P

Background

The three active agents (oxaliplatin, irinotecan and 5-FU/leucovorin) have demonstrated synergistic antitumor effects and could probably overcome resistance to doublet combination (FOLFOX/FOLFIRI) for mCRC. Preclinical studies have demonstrated that surufatinib (S, a small-molecule kinase inhibitor of VEGFR1-3, FGFR, and CSF-1R) plus chemotherapy have enhanced antitumor effects by regulating tumor microenvironment. This study aimed to evaluate the efficacy and safety of S plus chemotherapy, explore the difference between doublet vs triplet chemotherapy plus S for mCRC.

Methods

This open-label, 2-arm, phase II trial enrolled pts with mCRC who have progressed after standard first-line doublet chemotherapy. Pts are randomly allocated (1:1) to receive S (250 mg, once daily) in combination with mFOLFOX6/FOLFIRI (depending on first-line) in arm A, or with FOLFOXIRI in arm B, every 2 weeks until disease progression or unacceptable toxicity. Primary endpoint is ORR. Secondary endpoints include PFS, DCR, OS and safety. Simon 2-stage design is used. Each arm plans to enroll 28 pts in stage 1&2. If ≥7/28 pts experienced ≥PR, this arm is worth further investigation.

Results

As data cutoff of 31st Mar 2024, two arms have finished the enrollment (29 pts with 27 evaluable for efficacy and in arm A, 27 pts with 23 evaluable for efficacy in arm B).Median age was 63/60 years, 67/80% were male, 40/47% were ECOG PS 1 and 73/60% had ≥ 2 metastatic sites. The ORR was 25.93% (7/27; 1 CR and 6 PR) in arm A and 34.78% (8/23; 8 PR) in arm B, with DCRs of 81.5% and 82.6%, respectively. Median PFS was 5.52 months (95%CI 3.49-7.55) in arm A and 5.95 months (95%CI 5.63-6.27) in arm B. The most common TEAEs (Total; Grade ≥3) in arm A were anemia (55.17%; 0), neutropenia (44.83%; 13.79%), and leukopenia (41.38%; 3.4%); in arm B were leukopenia (66.67%; 22.22%), anemia (62.96%; 14.81%), and (62.96%; 40.74%).

Conclusions

Surufatinib plus either mFOLFOX6/FOLFIRI or FOLFOXIRI as second-line treatment in patients with mCRC reached its primary end point with acceptable safety profile. The promising results warrant further investigations in a large mCRC cohort.

Clinical trial identification

NCT04734249.

Legal entity responsible for the study

Fujian Cancer Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.